FIELD: immunology.
SUBSTANCE: disclosed is a chimeric antigen receptor (CAR) system which includes a receptor component comprising an antigen-binding domain, a transmembrane domain and a first binding domain; and also includes an intracellular signaling component comprising a CD3-zet endodomain and a second binding domain which specifically binds the first binding domain, wherein bonding of the first and second binding domains can be disturbed in the presence of a certain agent. Also presented is a CAR coding nucleic acid, an expression vector, T- and NK-cells, use thereof, method of producing T- or NK-cells and method of inhibiting CAR signaling system.
EFFECT: this group of inventions can be used in producing a drug for treating and/or preventing cancer diseases.
28 cl, 3 tbl, 4 ex, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
